By Fineline Cube 
China-based CF PharmTech, Inc., a specialist in inhalable drugs for respiratory diseases, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. The filing was jointly sponsored by CITIC Securities and CMB International, with key financial terms remaining undisclosed at this stage.
Company Overview
CF PharmTech focuses on the research, development, manufacturing, and commercialization of inhalable drugs targeting respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Its core product, CF017 (budesonide suspension for inhalation), has rapidly penetrated the market since its approval in May 2021. It achieved 16% market share in China’s budesonide inhalation sector in 2024. Another product, GW006, received FDA approval in May 2024 for COPD treatment.
Financial Performance
In 2024, CF PharmTech reported revenues of RMB 608 million (USD 85 million) and profits of RMB 21.09 million (USD 2.9 million), reflecting strong growth potential. The company allocated RMB 122 million (USD 17 million) to R&D activities, underscoring its commitment to expanding its pipeline of over 20 inhalable drug candidates.-Fineline Info & Tech